The European Commission (EC) has approved the use and marketing in Europe of Rixathon, a biosimilar to Roche’s MabThera (rituximab). The decision follows a positive review of Rixathon by the Committee for Medicinal Products for Human Use (CHMP) last April in response to Sandoz’s marketing application.
News
News
Nucala Triggered Remission in Eosinophilic Granulomatosis with Polyangiitis, But Not All Benefit
Nucala (mepolizumab) effectively induced remission in about half of patients with eosinophilic granulomatosis with polyangiitis (EGPA) that relapsed or did not respond to treatment, according to results from a Phase 3 clinical trial (NCT02020889). The study found that Nucala reduced…
Recent Posts
- Urinary C5a may help flag kidney disease severity in ANCA vasculitis
- UK advocates prepare for potential withdrawal of AAV therapy
- Nobody warned me about oral health problems related to vasculitis
- Approved EGPA treatment shows rapid benefits in severe cases
- AAV add-on therapy cuts steroid use, doesn’t boost kidney health